Cumberland Pharmaceuticals Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Cumberland Pharmaceuticals Inc. (CPIX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $481.32 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $196.14K, a 0.00% change year-over-year.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $285.18K, a 0.00% change year-over-year.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $285.19K, a 0.00% change year-over-year.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $374.23K, a 31.22% increase year-over-year.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.14M, a 0.00% change from fiscal 2024.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.14M, a 36.70% increase from fiscal 2023.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $834.50K.
- Cumberland Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $0.00.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $196.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $481.32K 10-Q · filed 2026-08-07 | $766.51K derived: sum of 3 quarters · filed 2026-08-07 | $1.14M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $285.18K 10-Q · filed 2026-05-08 | $570.37K derived: sum of 2 quarters · filed 2026-05-08 | $944.60K derived: sum of 3 quarters · filed 2026-05-08 | $1.14M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $285.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $659.41K derived: sum of 2 quarters · filed 2026-03-09 | $855.55K derived: sum of 3 quarters · filed 2026-08-07 | $1.14M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $374.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $570.37K derived: sum of 2 quarters · filed 2026-08-07 | $855.55K 10-Q · filed 2025-11-07 | $1.14M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $196.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $481.32K 10-Q · filed 2026-08-07 | $570.37K 10-Q · filed 2025-08-08 | $766.51K derived: sum of 3 quarters · filed 2026-08-07 | $1.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $285.18K 10-Q · filed 2026-05-08 | $570.37K derived: sum of 2 quarters · filed 2026-05-08 | $855.55K derived: sum of 3 quarters · filed 2026-05-08 | $1.14M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $285.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $570.37K derived: sum of 2 quarters · filed 2026-03-09 | $855.55K derived: sum of 3 quarters · filed 2026-03-09 | $1.14M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $285.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $570.37K derived: sum of 2 quarters · filed 2025-11-07 | $855.55K 10-Q · filed 2025-11-07 | $981.03K derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $285.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $570.37K 10-Q · filed 2025-08-08 | $695.85K derived: sum of 3 quarters · filed 2025-08-08 | $936.51K derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $285.18K 10-Q · filed 2025-05-09 | $410.66K derived: sum of 2 quarters · filed 2025-05-09 | $651.33K derived: sum of 3 quarters · filed 2025-05-09 | $947.48K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $125.48K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $366.14K derived: sum of 2 quarters · filed 2025-03-07 | $662.29K derived: sum of 3 quarters · filed 2025-03-07 | $834.50K 10-K · filed 2025-03-07 | |
| 2023-09-30 | $240.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $536.81K derived: sum of 2 quarters · filed 2024-11-08 | $709.02K 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $296.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $468.36K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $172.21K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |